AbCellera Biologics Inc.
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
About AbCellera Biologics
Pharmaceutical Preparations, SIC 2834
AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines for disease areas with high unmet medical needs. The company utilizes a vertically integrated technology platform that combines computational tools and laboratory research to discover antibodies from natural immune responses. Its internal pipeline features clinical-stage drug candidates, including ABCL635 for menopausal vasomotor symptoms and ABCL575 for atopic dermatitis, as well as preclinical candidates in autoimmunity and oncology. Additionally, the company collaborates with global biopharmaceutical and biotechnology partners to discover and advance therapeutic programs.
The company employs 562 full-time staff members representing more than 42 nationalities across Canada, Australia, and the United States. Its largest facilities are located in Vancouver, Canada, and Sydney, Australia. In Vancouver, the company maintains a 130,000-square-foot clinical manufacturing facility to support early-stage clinical trial supplies and platform operations. AbCellera has initiated more than 100 partner programs, with 19 molecules reaching clinical trials.
Summary of the business section of AbCellera Biologics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AbCellera Biologics Inc.
- Founded
- 2012
- Headquarters
- Vancouver, A1
- Address
- 150 W 4th Avenue V5Y 1G6
- Phone
- (604) 559-9005
- Website
- www.abcellera.com
- Employees
- 562, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- KPMG LLPChartered Professional Accountants, Vancouver, Canada
Stock & identifiers
- Ticker
- ABCL
- Exchange
- Nasdaq
- IPO date
- Dec 14, 2020
- Shares outstanding
- 307M, Aug 3, 2026
- Public float
- $789.23M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1703057
- CUSIP
- 00288U106
- ISIN
- US00288U1060
- LEI
- 9845000861BC95FF9F73
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carl L. G. Hansen | Chief Executive Officer, Director | 56,984,009 |
| Veronique Lecault | Chief Technology Officer, Director | 9,340,044 |
| Andrew Booth | Chief Financial Officer | 613,759 |
| Tryn Stimart | Chief Legal Officer | 500 |
| Michael R. Hayden | Director | 1,491,642 |
| John S. Montalbano | Director | 256,000 |
| Victor Sandor | Director | – |
| Lynn Seely | Director | – |
| Stephen Quake | Director | 1,100,436 |
| Andrew Lo | Director | 86,938 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 (1)Dr. Hansen | $6.29M | $7.27M | $2.68M | $9 | $120 |
| FY2024 (1)Dr. Hansen | $8.25M | -$347.46K | $3.25M | $7 | $91 |
| FY2023 (1)Dr. Hansen | $714.94K | -$14.62M | $664.28K | $14 | $92 |
| FY2022 (1)Dr. Hansen | $8.80M | -$12.52M | $4.71M | $25 | $89 |
| FY2021 (1)Dr. Hansen | $9.12M | -$122.89M | $4.07M | $36 | $99 |
| FY2020 (1)Dr. Hansen | $16.96M | $196.56M | $5.19M | $68 | $101 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 562 full-time employees in Canada, Australia, and the United States, representing over 42 nationalities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 28, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 14, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 8, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |